Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs MasterCard Inc (MA) Price & Performance

Eli Lilly And CoTrade
MasterCard IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs MasterCard Inc — how do they compare? Eli Lilly And Co trades at $1,160 (market cap $1.02T), while MasterCard Inc trades at $542.3 (market cap $483.71B). The key difference: Eli Lilly And Co is far larger — about 2.1× MasterCard Inc's market cap, and MasterCard Inc pays the higher dividend (0.64%). Which is the better fit depends on your goals.

LLYMA
Market Cap
$1.02T$483.71B
Sector
HealthConsumer Cyclical
52-Week High
$1.24K$598.96
52-Week Low
$625.65$471.55
Enterprise Value
$1.06T$494.45B
Dividend Yield
0.6%0.64%
Volume
4,635,698

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

MasterCard Inc

Mastercard (MA) trades at $541.40, down 0.4% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue growth remains solid, climbing to $32.79 billion in 2025, while maintaining high net income margins above 45%. Recent news highlights Mastercard's AI initiatives in ASEAN and commitment to financial inclusion, targeting 500 million more underbanked individuals by 2030.

The investment outlook is positive, driven by consistent earnings outperformance, expanding profit margins, and a dominant market position. Risks include competitive pressures from emerging payment technologies like stablecoins and elevated valuation multiples. Analyst consensus is strongly bullish with a $634.27 price target, suggesting ~17% upside from current levels. Institutional accumulation continues, though investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA